Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.

ABSTRACT:

Background

The manipulation of dendritic cells (DCs) for cancer vaccination has not reached its full potential, despite the revolution in cancer immunotherapy. DCs are fundamental for CD8+ T cell activation, which relies on cross-presentation of exogenous antigen on MHC-I and can be fostered by immunogenic cancer cell death. Translational and clinical research has focused on in vitro-generated monocyte-derived DCs, while the vaccination efficacy of natural conventional type 1 DCs (cDC1s), which are associated with improved anti-tumor immunity and specialize on antigen cross-presentation, remains unknown.

Methods

We isolated primary spleen mouse cDC1s and established a protocol for fast ex vivo activation and antigen-loading with lysates of tumor cells that underwent immunoge

SUBMITTER: Wculek SK 

PROVIDER: S-EPMC6454603 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature